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Background. Based on recent basic and clinical investigations, the extract of artichoke (Cynara scolymus) leaf has been revealed to be
used for hepatoprotective and cholesterol reducing purposes.We aimed to assess the therapeutic effects of artichoke on biochemical
and liver biomarkers in patients with nonalcoholic steatohepatitis (NASH). Methods. In a randomized double blind clinical trial,
60 consecutive patients suffering NASH were randomly assigned to receive Cynara scolymus extract (as 6 tablets per day consisting
of 2700mg extract of the herb) as the intervention group or placebo as the control group for two months. Results. Comparing
changes in study markers following interventions showed improvement in liver enzymes.The levels of triglycerides and cholesterol
were significantly reduced in the group treated with Cynara scolymus when compared to placebo group. To compare the role of
Cynara scolymus use with placebo in changes in study parameters, multivariate linear regression models were employed indicating
higher improvement in liver enzymes and also lipid profile particularly triglycerides and total cholesterol following administration
of Cynara scolymus in comparison with placebo use. Conclusion. This study sheds light on the potential hepatoprotective activity
and hypolipidemic effect of Cynara scolymus in management of NASH.This clinical trial is registered in the IRCT, Iranian Registry
of Clinical Trials, by number IRCT2014070218321N1.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) refers to a wide
spectrum of disorders characterized by fatty infiltration in
the liver and steatosis [1]. By developing oxidative stress,
hepatocellular inflammation, and steatosis, the term was
replaced by nonalcoholic steatohepatitis (NASH) that may
culminate in cirrhosis and hepatocellular carcinoma [2, 3].
Within the last decade, prevalence of NASH has interestingly
doubled especially in the Middle East, Far East, Africa, the
Caribbean, and Latin America due to its close association
with lifestyle disorders such as diabetes and obesity [4].
In this regard, the best treatment approaches for this phe-
nomenon include weight loss, changes in dietary regimens,
and lifestyle modifications. Also, in cases with documented
hyperlipidemia or diabetes, use of insulin sensitizing and
lipid lowering drugs can be also considered [5]. However,
since NASH is a multifactorial disorder, single target based
therapy has limited implications. Hence, the use of herbal
medicine approach can be a promising alternative due to its
multipronged mechanisms of action [6–8].
Artichoke (Cynara scolymus) is a plant frequently grown
inMediterranean countries that is rich in natural antioxidants
and thus is used as a herbal drug [9]. Based on recent
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basic and clinical investigations, the extract of artichoke
leaf has been revealed to be used for hepatoprotective [10–
12], antimicrobial [13], and cholesterol reducing purposes
[14].
Artichoke has been found to decrease the production of
reactive oxygen species, the oxidation of low-density lipopro-
teins [15], lipid peroxidation [11], and protein oxidation and
increase the activity of glutathione peroxidase [16]. In this
regard, it seems that the use of this herb may be promising to
treatNASH.Thepresent study aimed to assess the therapeutic
effects of artichoke on biochemical and liver biomarkers in
patients with NASH.
2. Subjects and Methods
2.1. Study Population. In a randomized double blind clinical
trial, 60 consecutive patients who suffered NASH (based on
changes in liver enzymes and sonographic evidences) were
included in the study. The main inclusion criteria were ele-
vation of liver enzymes (>30 𝜇/L), any evidences of fatty liver
in abdominal sonography, and the existence of at least one
of these characteristics: total cholesterol > 200mg/dL, high
density lipoprotein (HDL) < 40mg/dL for men and <50mg/
dL for women, serum triglycerides level > 150mg/dL, fasting
blood sugar > 100mg/dL, obesity defined as body mass index
> 30 kg/m2, or blood pressure > 130/85mmHg. In this regard,
the main exclusion criteria were daily alcohol consumption,
diabetes mellitus type I, the existence of concomitant liver
diseases such as hepatitis B or C, autoimmune hepatitis,
Wilson, hemochromatosis, alpha-1 antitrypsin deficiency, or
biliary obstruction, the use of vitamin C, livergol, hepatotoxic
drugs, NASH inducing drugs such as amiodarone, calcium-
channel blockers, or tamoxifen, pregnancy or breastfeeding,
sensitivity to artichoke species, or any life-threatening disor-
ders.
The two groups werematched in terms of sex distribution
(21 male and 9 female in both groups) and mean age (47.27 ±
8.12 years in intervention group and 49.83 ± 12.79 years in
placebo group, 𝑃 = 0.357). The two groups were also similar
in other baseline characteristics including weight, levels of
liver enzymes, lipid profile, and fasting blood sugar on initial
assessment.
2.2. Study Intervention. The baseline characteristics of
patients were collected by interviewing and the study ques-
tionnaires were recorded. The patients were then randomly
assigned to receive Cynara scolymus extract (as 6 tablets per
day consisting of 2700mg extract of the herb prepared in
Dineh company, Qazvin, Iran) as the intervention group
or placebo as the control group for two months (placebo
was prepared from the same ingredient as treatment except
Cynara scolymus extract). The randomization was done
using computer generated random number tables. Both
groups were advised to maintain regular physical activity
(20min walking within 5 days a week) and an appropriate
dietary regimen (calculated based on patients’ weight, height,
age, and percentage of activity using the Mifflin formula to
gradually reduce body weight).
2.3. Measurement of Biomarkers. Serum alanine transam-
inase (ALT) and aspartate transaminase (AST) activity
was estimated colorimetrically using an especial kit (Pars
Azmoon company, Iran) according to themethod of Reitman
and Frankel [17]. Serum cholesterol (Chol) concentration
was determined colorimetrically using an especial kit (Pars
Man company, Iran) according to the method of Allain et
al. [18]. Serum LDL-cholesterol (LDL) concentration was
assayed colorimetrically using an especial kit (Pars Azmoon
company, Iran) according to the method of Assmann et
al. [19]. Serum HDL-cholesterol (HDL) concentration was
measured colorimetrically using an especial kit (Pars Man
company, Iran) according to the method of Lopez-Virella
et al. [20]. Serum triglycerides (TG) level was determined
colorimetrically using an especial kit (Pars Azmoon com-
pany, Iran) according to the method of Fassati and Prencipe
[21]. The biomarkers were measured at the two time points:
admission time and 2 months after the initial assessment
(completing treatment protocols).
2.4. Statistical Analysis. Results were presented as mean ±
standard deviation (SD). Continuous variables were com-
pared using 𝑡-test or nonparametric Mann-Whitney 𝑈 test.
The changes in study biomarkers after interventions were
assessed using the Paired 𝑡-test or nonparametric Wilcoxon
test. The multivariate linear regression analysis was used
for assessing study outcomes following different employed
protocols as follows. First, the baseline variables as probable
confounders with a 𝑃 value <0.20 in univariate analyses
were taken in a multivariate logistic regression model to
assess the difference between the treatment groups receiving
Cynara scolymus extract or placebo with the presence of
these confounders. For the statistical analysis, the statistical
software SPSS version 21.0 for windows (SPSS Inc., Chicago,
IL) was used.
3. Results
As shown in Table 1, following administration of Cynara
scolymus, significant reduction was observed inmean weight,
as well as in serum levels of ALT, AST, blood sugar, total
cholesterol, LDL, and triglycerides. Also, mean systolic blood
pressure was significantly reduced using Cynara scolymus. In
contrast, using placebo resulted in significant reduction in
mean weight, as well as in serum levels of ALT and AST;
however, among other biomarkers, blood sugar and lipid
profile remained unchanged. Comparing changes in study
markers following interventions showed the changes in liver
enzymes, and also levels of triglycerides and cholesterol were
significantly more in group treated with Cynara scolymus
when compared to placebo group (Table 2). To compare
the role of Cynara scolymus use with placebo in changes
in study parameters, multivariate linear regression models
were employed (Table 2) indicating higher improvement in
liver enzymes and also lipid profiles of triglycerides and total
cholesterol following administration of Cynara scolymus in
comparison with placebo use.
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Table 1: Changes in study biomarkers in intervention and placebo groups.
Marker Intervention group Placebo group Intergroup difference
Before After 𝑃 value Before After 𝑃 value
Weight (kg) 83.90 ± 15.83 79.28 ± 14.25 <0.001 81.81 ± 14.25 77.05 ± 14.83 <0.001 0.859
ALT (mg/dL) 81.77 ± 38.73 38.40 ± 14.15 <0.001 74.13 ± 23.61 64.07 ± 20.36 <0.001 <0.001
AST (mg/dL) 45.53 ± 13.78 24.60 ± 7.43 <0.001 44.50 ± 9.82 39.60 ± 10.41 <0.001 <0.001
FBS (mg/dL) 108.07 ± 28.90 97.60 ± 14.50 0.029 107.43 ± 18.48 102.57 ± 10.78 0.096 0.302
Chol (mg/dL) 206.47 ± 31.20 182.87 ± 34.64 0.001 213.67 ± 48.48 211.63 ± 48.96 0.686 0.008
LDL (mg/dL) 122.14 ± 30.42 108.12 ± 32.36 0.039 116.09 ± 29.38 113.23 ± 31.79 0.659 0.120
HDL (mg/dL) 45.87 ± 10.46 43.33 ± 8.20 0.129 45.50 ± 7.50 44.87 ± 6.10 0.689 0.403
TG (mg/dL) 193.37 ± 86.03 154.50 ± 84.93 0.011 179.87 ± 45.67 184.23 ± 57.83 0.659 0.016
SBP (mg/dL) 132.70 ± 13.55 126.57 ± 8.54 0.004 130.23 ± 10.34 128.20 ± 6.62 0.044 0.070
DBP (mg/dL) 80.00 ± 9.21 79.03 ± 6.89 0.578 80.87 ± 8.52 81.63 ± 7.31 0.504 0.403
Table 2: Multivariate linear regression models for determining the role of Cynara scolymus use on changes in liver enzymes and lipid profile.
Marker Variable Beta 95% confidence interval 𝑃 value
ALT change
Artichoke use −31.365 −45.201 to −17.528 <0.001
Male sex −0.634 −16.252 to 14.983 0.935
Age −0.754 −1.434 to −0.074 0.030
AST change
Artichoke use −16.041 −21.405 to −10.677 <0.001
Male sex −2.995 −9.049 to 3.060 0.326
Age 0.003 −0.261 to 0.266 0.983
Chol change
Artichoke use −21.673 −37.245 to −6.101 0.007
Male sex −17.072 −34.648 to 0.505 0.057
Age 0.041 −0.723 to 0.806 0.914
TG change
Artichoke use −41.960 −76.613 to −7.307 0.019
Male sex −28.315 −67.428 to 10.798 0.153
Age −0.496 −2.198 to 1.206 0.562
4. Discussion
Our study aimed to assess the beneficial effects of Cynara
scolymus, a herb with antioxidant compounds, on liver
function and also lipid profile and fasting blood glucose.
On the other hand, we aimed to demonstrate therapeutic
effects of this herb on liver functional biomarkers and also
hemodynamic parameters in patients with NASH. In this
double blind clinical trial, patients in intervention group
receivedCynara scolymus extract for twomonths and changes
in study biomarkers were reassessed.
Serum ALT and AST are effective biomarkers in the
diagnosis of hepatic damage. Sever liver damage was demon-
strated by remarkable elevation of serum ALT and AST
levels. This elevation may be attributed to the release of these
enzymes from the cytoplasm in to the blood circulation after
rupture of the plasma membrane and cellular damage [22].
The result of the present study showed significant changes
in serum ALT and AST levels in intervention group in com-
parison with the placebo group (𝑃 < 0.001). This effect could
be attributed to the antioxidant ingredients in Cynara scoly-
mus extract such asmono- and dicaffeoylquinic acid (cynarin
and chlorogenic acid), caffeic acid and flavonoids includ-
ing the glycosides luteolin-7-𝛽-rutinoside (scolymoside),
luteolin-7-𝛽-D-glucoside, and luteolin-4-𝛽-D-glucoside that
are mainly compounds in Cynara scolymus extract [23–25].
And chlorogenic acid is themost active antioxidant inCynara
scolymus extract [26]. Antioxidants are components that
prevent oxidative reactions often by scavenging free radicals
before they can damage cells [27, 28]. Several in vitro and
animal studies assessed the antioxidative and free radical
scavenging potential of artichoke extracts in protection hep-
atocytes from oxidative stress [29–32], but there are a few
human and clinical studies in this regard. The result of the
present study in reduction of serum ALT and AST levels is
in agreement with Saffa et al. They investigate the efficacy
of Cynara scolymus total methanolic extract (CSM) and its
fraction (CSF) in rat. Their result showed that CSF is more
active in comparison with CSM. Perhaps it is because of
high concentration of monocaffeoylquinic acid derivatives
(chlorogenic acid) in CSF [33]. In Huber’s study although the
used doses of Cynara scolymus extract and duration of study
were more than the present study, remarkable reduction in
serum ALT and AST levels was not seen in patients with
hepatitis C, which is not in agreement with our study. It
appears that because of microbial agent and sever damage
of hepatocytes uneffectiveness of Cynara scolymus extract
on ALT and AST was caused [34]. Also, in present study,
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improvement of lipid profile was significantly observed in
the group receiving Cynara scolymus extract not in placebo
group. These effects could be attributed to active ingredi-
ents in Cynara scolymus extract which are known as caf-
feoylquinic acid derivatives (cynarin and chlorogenic acid).
Some previous studies showed that these compounds can
reduce cholesterol by inhibiting HMG-COA reductase and
having a hypolipidemic influence lowering blood cholesterol
[26].
Our result on hypocholesterolemic effect of Cynara scoly-
mus extract is in agreement with Pittler et al. [35]. Some
studies suggest that Cynara scolymus extract reduces blood
lipids by directly influencing biosynthesis of cholesterol and
also by production and secretion of bile from the liver [36, 37].
Reduction in triglycerides level is attributed to improvement
in glycemic control and reduction of glucose instead of
fat. Acetyl COA yield from pyruvic acid enters Krebs cycle
and leads to metabolism of glucose completely instead of
triglycerides biosynthesis.
In present study improvement in fasting blood sugar was
significantly observed in group receiving Cynara scolymus
extract not in placebo group. This beneficial effect could be
attributed to high antioxidant capacity of this herb. Phenolic
compounds, specially, such as caffeic acid and flavonoids, are
representative of this effect.
Anothermechanism for reducing glucose level byCynara
scolymus extract is affecting glucose absorption. Antioxidant
compounds delay depletion of stomach and bowels and
they inhibited 𝛼-amylase and 𝛼-glucosidase enzymes in
bowels and blocked glucose transportation to blood. On the
other hand antioxidants have insulin-like effect and increase
glucose absorption in peripheral tissue. Another probable
mechanism is influencing𝛽-cells, repairing damage cells, and
stimulating these cells to secrete insulin. Studies show that
chlorogenic acid has antidiabetic effect [38, 39] and reduction
glucose by reason of this compound.
Another point of this study was the parallel improvement
in liver enzymes and also lipid profile by administrating
Cynara scolymus that was not simultaneously in placebo
group. Cholesterol metabolism is associated with liver fat
content independent of body weight, implying that the
more the fat the liver contains, the higher the cholesterol
synthesis is [40]. Cellular cholesterol synthesis is regulated
by activation of membrane bound transcription factors, des-
ignated sterol regulatory element-binding proteins (SREBPs)
which are the most abundant in the liver [41], and the
excess of cellular cholesterol is esterified by the acyl CoA-
cholesterol acyltransferase (ACAT) [42]. The high level of
cholesterol synthesis and the increased SREBP-2 activity have
paradoxically been shown in subjects with NASH [43]. It is
thus suggested that the effects ofCynara scolymusmay appear
by inducing and involving these metabolic pathways in the
liver.
The main strength of the study was to shed light on
the potential role of artichoke on biochemical and liver
biomarkers in patients with NASH in a controlled trial.
Although, in previous studies, the role of this herb to treat
NASHhas been assessed, a few studies focused directly on the
improvement of liver enzymes via administrating this herbal
drug. Another strength of the current study was to assess the
simultaneous changes in liver enzymes, blood sugar, and lipid
profile.This concomitant assessment is important because the
central role of liver leads to metabolic pathways regulating
the level of these metabolic biomarkers. However, our study
had some potential limitations including small sample size
leading to partially low study power as well as ignoring other
baseline clinical and pharmacological confounders affecting
the employed regressionmodels used for assessing the effects
of artichoke on biochemical and liver biomarkers in NASH.
5. Conclusion
In conclusion, the current study sheds light on the potential
role of Cynara scolymus in management of NASH.The active
constituents of this herb such as flavonoids and caffeoylquinic
acid may be responsible for this effect. These compounds
have been proven to have hepatoprotective activity and
hypolipidemic effect.
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